Associated Papers
Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility.
Varghese V et al.
Aids Research and Human Retroviruses, 2016
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
Ntemgwa M et al.
Antimicrobial Agents and Chemotherapy, 2007
Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure.
Holguín A et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 2006
Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia.
Tee KK et al.
Aids Research and Human Retroviruses, 2006
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.
Lecossier D et al.
Journal of Acquired Immune Deficiency Syndromes (1999), 2005
Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.
Kapoor A et al.
Journal of Virology, 2004
Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
Bally F et al.
Aids Research and Human Retroviruses, 2000
Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.
Middleton T et al.
Hiv Clinical Trials, 0
Select a paper to view details